版本:
中国

BRIEF-Microbix Biosystems says consulted with FDA to return its thrombolytic biologic drug to U.S. market

May 1 Microbix Biosystems Inc

* Microbix Biosystems Inc - consulted with FDA regarding plans to return its thrombolytic biologic drug, kinlytic urokinase to U.S. market

* Microbix Biosystems Inc - already received expressions of interest to license or acquire kinlytic and to provide full funding for its re-launch program Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐